Abstract：
:Desmoplastic small round cell tumor (DSRCT) is a rare and aggressive malignancy with poor outcome occurring in adolescents and young adults. Therapeutic options for patients with advanced disease are limited. Preclinical studies have shown that VEGFR-2 and VEGFA are overexpressed in DSRCT and that DSRCT xenografts were highly responsive to anti-VEGF agents such as bevacizumab. We report here the clinical activity of sunitinib in eight patients with DSCRT. Our data suggest that sunitinib may be associated with clinical benefit even in heavily pretreated patients.
journal_name
Target Oncoljournal_title
Targeted oncologyauthors
Italiano A,Kind M,Cioffi A,Maki RG,Bui Bdoi
10.1007/s11523-012-0251-8subject
Has Abstractpub_date
2013-09-01 00:00:00pages
211-213issue
3eissn
1776-2596issn
1776-260Xpii
10.1007/s11523-012-0251-8journal_volume
8pub_type
杂志文章abstract：:Obinutuzumab (Gazyva®, Gazyvaro®) is a recombinant, monoclonal, humanized and glycoengineered, type II, anti-CD20, IgG1 antibody. It has recently been granted an additional indication for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. In the...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-017-0485-6
更新日期：2017-04-01 00:00:00
abstract：BACKGROUND:Immunotherapy based on programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has revolutionized the treatment of non-small cell lung cancer (NSCLC). Patients with high PD-L1 expression or DNA mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) cancer are re...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-020-00703-3
更新日期：2020-02-01 00:00:00
abstract：:The advent of imatinib mesilate, an oral target therapy, has dramatically changed the natural history of gastrointestinal stromal tumours (GISTs). This rare neoplasm has become the paradigm of targeted therapies in solid tumours, also introducing a home-based cure concept in oncology. However, it should be retained th...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-012-0221-1
更新日期：2012-12-01 00:00:00
abstract：:Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) catalyze the first rate-limiting step in the oxidative metabolism of compounds containing indole rings, including the transformation of the essential amino acid L-tryptophan to N-formyl-L-kynurenine. Through direct and indirect means, IDO exerts bo...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-017-0547-9
更新日期：2018-04-01 00:00:00
abstract：:The First-Line Erbitux in Lung Cancer (FLEX) trial showed that the addition of cetuximab to chemotherapy followed by weekly cetuximab maintenance significantly improved survival in the first-line treatment of advanced non-small cell lung cancer (NSCLC). The phase IIIb NSCLC Erbitux Trial (NEXT) trial (NCT00820755) inv...
journal_title：Targeted oncology
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1007/s11523-014-0336-7
更新日期：2015-06-01 00:00:00
abstract：:The currently prevalent somatic mutation theory of carcinogenesis and metastases explicitly assumes that cancer is a cellular disease, i.e. a disease of the control of cell proliferation and/or cell differentiation. Accordingly, explanations should always be sought for at a gene and/or gene product level, regardless o...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-013-0277-6
更新日期：2013-06-01 00:00:00
abstract：:Several angiogenesis inhibitors have been approved for commercial use and many additional agents are under development for the treatment of various malignancies. Cardiovascular toxicities have been increasingly recognized as effects of this entire class of new anticancer therapeutics. There is a limited but growing un...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-009-0106-0
更新日期：2009-04-01 00:00:00
abstract：:Non-small cell lung cancer (NSCLC) has recently been associated with interesting molecular characteristics that have important implications in carcinogenesis and response to targeted therapies. Targeted therapies, if given to a patient subpopulation enriched by the presence of relevant molecular targets, can often abr...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-013-0263-z
更新日期：2013-03-01 00:00:00
abstract：:The poly(ADP-ribose) polymerase inhibitor rucaparib is approved as monotherapy in the treatment and maintenance settings for women with relapsed ovarian cancer in the European Union and the United States. We review the safety profile of rucaparib in both settings and provide recommendations for the clinical management...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-020-00715-z
更新日期：2020-06-01 00:00:00
abstract：BACKGROUND:Peripheral T-cell lymphoma (PTCL) is associated with poor prognosis, particularly in patients with relapsed/refractory (R/R) disease. Pralatrexate, a folate analogue inhibitor, was the first drug approved to treat R/R PTCL. OBJECTIVE:As the distribution of PTCL subtypes differs between populations and few p...
journal_title：Targeted oncology
pub_type： 杂志文章,多中心研究
doi：10.1007/s11523-019-00630-y
更新日期：2019-04-01 00:00:00
abstract：BACKGROUND:The identification of prognostic and/or predictive biomarkers for response to immune checkpoint inhibitors (ICI) could help guide treatment decisions. OBJECTIVE:We assessed changes in programmed cell death-1 (PD1)/PD1 ligand (PDL1) expression in key immunomodulatory cell subsets (myeloid-derived suppressor ...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-018-0595-9
更新日期：2018-10-01 00:00:00
abstract：:Data regarding the expression of epidermal growth factor receptor (EGFR) in melanoma and its role in the tumor biology are conflicting. In BRAF V600-mutant melanomas, the expression of EGFR has been associated with acquired resistance to BRAF inhibitors. In this study, we assessed EGFR expression and downstream signal...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-014-0318-9
更新日期：2015-03-01 00:00:00
abstract：BACKGROUND:Sunitinib (S) is a multi-targeted tyrosine kinase inhibitor. It is synergistic with chemotherapy in preclinical models. We hypothesized that sunitinib in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) would be a tolerable and effective regimen in advanced gastric and gastroesophageal jun...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-019-00692-y
更新日期：2020-02-01 00:00:00
abstract：:Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced stages. Chemotherapeutic agents such as doxorubicin are currently used as first-line agents for HCC therapy, but these are non-selective cytotox...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-016-0452-7
更新日期：2017-02-01 00:00:00
abstract：:Vemurafenib, a specific inhibitor of mutated BRAF kinase, may activate wild-type BRAF and therefore induce squamous cell skin carcinomas in patients treated for melanoma. All vemurafenib clinical trials excluded patients with multiple primary malignant tumors; therefore, the action of this drug on concurrent BRAF wild...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-015-0384-7
更新日期：2016-04-01 00:00:00
abstract：BACKGROUND:Cancer is a multifactorial disease, which makes it difficult to cure. Since more than one defective cellular component is often involved during oncogenesis, combination therapy is gaining prominence in the field of cancer therapeutics. OBJECTIVE:The purpose of this study was to investigate the combinatorial...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-016-0441-x
更新日期：2016-10-01 00:00:00
abstract：:The influence of tumor infiltrating lymphocytes on tumor growth and response to therapy is becoming increasingly apparent. While much work has focused on the role of T cell responses in anti-tumor immunity, the role of B cells in solid tumors is much less understood. Tumor infiltrating B cells have been found in a var...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-017-0481-x
更新日期：2017-04-01 00:00:00
abstract：BACKGROUND:Axitinib, an inhibitor of vascular endothelial growth factor (VEGF) receptors, is approved as second-line treatment for advanced renal cell carcinoma (RCC). Agents targeting the VEGF pathway may induce renal toxicities, which may be influenced by pre-existing renal dysfunction. OBJECTIVE:The objective was t...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-015-0389-2
更新日期：2016-04-01 00:00:00
abstract：:Differentiated thyroid carcinoma is the most frequent neoplasm of the endocrine system. Although thyroid cancer usually has an excellent prognosis, no therapeutic options are available for patients that develop metastases and are or became resistant to radioiodine therapy. The deeper knowledge of molecular aberrations...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-009-0124-y
更新日期：2009-12-01 00:00:00
abstract：:Hypoxia is a critical hallmark of solid tumors and involves enhanced cell survival, angiogenesis, glycolytic metabolism, and metastasis. Hyperbaric oxygen (HBO) treatment has for centuries been used to improve or cure disorders involving hypoxia and ischemia, by enhancing the amount of dissolved oxygen in the plasma a...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-012-0233-x
更新日期：2012-12-01 00:00:00
abstract：:The selective BRAF inhibitors vemurafenib and dabrafenib yield high response rates and improved overall survival in patients with BRAF V600E-mutant metastatic melanoma. Treatment traditionally continues until disease progression or the development of unacceptable toxicity. Acquired drug resistance and toxicity are key...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-015-0410-9
更新日期：2016-08-01 00:00:00
abstract：:Chemotherapy represents the mainstay of non-small cell lung cancer (NSCLC) treatment, but response is usually observed in only one out of three patients. Massive efforts have been carried out to identify biomarkers that might help clinicians to choose appropriate drugs, by identifying potentially sensitive subjects an...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-010-0132-y
更新日期：2010-03-01 00:00:00
abstract：BACKGROUND:Serum protein fraction (SPF) is a common parameter reflecting the nutritional and inflammatory status of the human body. However, its role in patients with cancer, particularly those treated with targeted agents, is unknown. OBJECTIVE:We conducted this study to explore the prognostic value of SPF in patient...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-019-00625-9
更新日期：2019-04-01 00:00:00
abstract：:Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Efficacy of this drug was documented in the BR.21 trial showing that adenocarcinoma, female gender, Asian ethnicity and never-smoker status are predictive of clinical response to erlotinib. Retrospective studies documented the same bene...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-010-0163-4
更新日期：2010-12-01 00:00:00
abstract：BACKGROUND:Golgi phosphoprotein 2 (GOLPH2) has been shown to be involved in chronic inflammatory processes and carcinogenesis. GOLPH2 is prominently overexpressed in hepatocellular carcinoma, melanoma, glioblastoma, prostate, lung, and colorectal cancer. With a low and tightly regulated expression in non-malignant tiss...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-019-00667-z
更新日期：2019-10-01 00:00:00
abstract：:In subsets of gastrointestinal stromal tumors (GISTs), mutations of the KIT and PDGFRA receptor tyrosine kinases correlate with tumor prognosis and response to tyrosine kinase inhibitors (TKIs). Determining genotypes in TKI-resistant GISTs is challenging due to the potential risks and limitations of repeated biopsies ...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-015-0361-1
更新日期：2015-12-01 00:00:00
abstract：BACKGROUND:A consistent percentage of patients with metastatic non-small cell lung cancer (NSCLC) derives no or only marginal benefit from immunotherapy (IO). OBJECTIVE:Since serum sodium has been linked to both prognosis in NSCLC and modulation of immune cells activity, we aimed to assess the association between low ...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-018-0599-5
更新日期：2018-12-01 00:00:00
abstract：BACKGROUND:The WEE1 inhibitor adavosertib (AZD1775) has been investigated in Western patients. OBJECTIVE:This open-label Phase Ib study (NCT02341456) investigated the safety, pharmacokinetics, and clinical activity of adavosertib in combination with carboplatin alone or paclitaxel plus carboplatin in Asian patients wi...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-020-00701-5
更新日期：2020-02-01 00:00:00
abstract：:We aimed to assess the prognostic role of pretreatment neutrophilia, lymphocytopenia, and neutrophil to lymphocyte ratio (NLR) in patients treated with vascular endothelial growth factor-tyrosine kinase inhibitors (VEGFR-TKIs) for late relapsing (>5 years) metastatic renal cell carcinoma (mRCC). Data were collected fr...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-014-0356-3
更新日期：2015-12-01 00:00:00
abstract：:δ-Catenin is the only member of the p120 catenin (p120ctn) subfamily whose normal pattern of expression is restricted to the brain. Similar to p120ctn, δ-catenin can bind to the juxtamembrane domain of E-cadherin. We examined the expression of δ-catenin, p120ctn, and E-cadherin using immunohistochemistry in 95 cases o...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-013-0269-6
更新日期：2014-03-01 00:00:00
